Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2

التفاصيل البيبلوغرافية
العنوان: Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2
المؤلفون: Cédric Cleyrat, Jaroslav Jelinek, François Girodon, Marjorie Boissinot, Thierry Ponge, Jean-Luc Harousseau, Jean-Pierre Issa, Sylvie Hermouet
المصدر: Blood. 114:3908-3908
بيانات النشر: American Society of Hematology, 2009.
سنة النشر: 2009
مصطلحات موضوعية: Genetics, Silent mutation, Mutation, Immunology, Mutant, Haplotype, food and beverages, Cell Biology, Hematology, Biology, medicine.disease_cause, medicine.disease, Biochemistry, Molecular biology, Exon, genomic DNA, Polycythemia vera, hemic and lymphatic diseases, medicine, Allele, hormones, hormone substitutes, and hormone antagonists
الوصف: Abstract 3908 Poster Board III-844 Background In more than 95% of cases, Polycythemia vera (PV) is characterized by the presence of the V617F mutation of JAK2 (JAK2-V617F). We report on three cases of V617F-positive PV with an additional mutation of JAK2 changing leucine 611 for a valine (L611V). Design and Methods We used allele-specific quantitative PCRs and pyro-sequencing to detect the L611V and V617F JAK2 mutants in genomic DNA and in cloned PCR products. The consequences of the different mutations on the function of JAK2 were investigated using transient expression in BaF-3/EpoR cells. Results We found equal proportions of L611V and V617F alleles in granulocyte DNA (patients Na249, 19%; Na382, 26%; Di362, 27%) and established the presence of alleles with L611V and V617F in cis (L611V/V617F). The double JAK2-L611V/V617F mutant represented 15% to 26% of JAK2 alleles in granulocyte DNA. JAK2-L611V/V617F was detected in 12% to 30% of erythroid colonies, always in a heterozygous fashion. Low levels of single mutant alleles were also found, in 0.5% of cloned PCR products (JAK2-L611V, patient Na249) and in 1.5% of genomic DNA and cloned PCR products (JAK2-V617F, patient Na249), indicating that mutations in JAK2 occurred more than once. Functionally, JAK2-L611V was found comparable to wild-type JAK2, whereas JAK2-L611V/V617F displayed greater constitutive tyrosine phosphorylation of JAK2 and AKT than wild-type JAK2 and JAK2-V617F. The double JAK2-L611V/V617F mutant was associated with a high hematocrit and normal counts of leukocytes and platelets. Patients Na382 and Di362, but not patient Na249, carried the 46/1 haplotype of chromosome 9p associated with a reported pre-disposition to mutations of JAK2 on the same allele. Conclusion PV patients can harbor multiple clones carrying different mutations of JAK2, which may or may not increase JAK2 activity. Functionally silent mutations, not leading to clonal expansion, may remain undetected. The double JAK2-L611V/V617F mutated clone was predominant whereas single L611V and V617F JAK2 mutants represented Disclosures: No relevant conflicts of interest to declare.
تدمد: 1528-0020
0006-4971
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f4eb252f1b13938fe44dcce8efad629aTest
https://doi.org/10.1182/blood.v114.22.3908.3908Test
رقم الانضمام: edsair.doi...........f4eb252f1b13938fe44dcce8efad629a
قاعدة البيانات: OpenAIRE